Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02795156 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02795156 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 100 participants.
The verdict
NCT02795156, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients. If a genomic alteration is identified during profiling, it could help guide the choice of therapy and improve treatment outcomes. This study will examine the anti-tumor activity of selected commercially available molecularly matched targeted therapies in patients who have failed first-line treatment for one of the following tumor types: non-small cell lung cancers; urothelial cancer; non-colon gastrointestinal cancers, and upper aerodigestive tract cancer.
Interventions
- DRUG Regorafenib
- DRUG Cabozantinib
- DRUG Afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02795156
The ClinicalTrials.gov registry entry for NCT02795156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib is the first listed.
NCT02795156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02795156 about?
NCT02795156 is a clinical study titled "Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations". With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients. If a genomic alteration is identified during profiling, it could help guide the choice of therapy and improve treatment outcomes. This study ...
What is the current status of trial NCT02795156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-09-28. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT02795156?
The interventions under investigation include: Regorafenib (DRUG), Cabozantinib (DRUG), Afatinib (DRUG).
Who is sponsoring clinical trial NCT02795156?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.